10-Q: DermTech Reports Q1 2024 Results, Revenue Up Slightly Amid Restructuring

DermTech's Q1 2024 revenue increased slightly to $3.8 million, but the company faces substantial doubt about its ability to continue as a going concern.

Summary

• DermTech reported a net loss of $20.0 million for the three months ended March 31, 2024, compared to a net loss of $31.27 million for the same period in 2023.
• Total revenue increased by 11% to $3.845 million, driven by a 7% increase in test revenue to $3.677 million and a significant increase in contract revenue.
• The company's cost of revenues decreased by 18% to $3.132 million.
• Operating expenses decreased by 33% to $21.221 million, primarily due to reductions in sales and marketing, research and development, and general and administrative expenses.
• The company's cash and cash equivalents totaled $27.6 million, and short-term marketable securities totaled $11.4 million as of March 31, 2024.
• The company has implemented multiple restructuring plans, including workforce reductions, to align resources and reduce operating expenses.
• DermTech is exploring strategic alternatives to address its financial challenges.
• The company acknowledges substantial doubt about its ability to continue as a going concern within the next 12 months without additional funding or a strategic transaction.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial challenges, going concern warning, and potential Nasdaq delisting, despite some positive aspects like revenue growth and expense reductions.

Positives

• Revenue increased by 11% compared to the same period last year.
• Operating expenses were significantly reduced due to restructuring efforts.
• Net loss decreased by 36% year-over-year.
• Test revenue increased due to higher average selling prices and prioritization of billable sample volume with contracted payors.
• Contract revenue increased due to a higher number of kit shipments to contract research customers.

Negatives

• The company reported a net loss of $20.0 million for the quarter.
• Billable test revenue samples decreased by 14% compared to the same period last year.
• The company acknowledges substantial doubt about its ability to continue as a going concern.
• The company received a deficiency letter from Nasdaq due to its stock price falling below $1.00 per share.

Risks

• The company's ability to continue as a going concern is uncertain without additional funding or a strategic transaction.
• Failure to achieve expected cost savings from restructuring plans could adversely affect the company's financial condition.
• The exploration of strategic alternatives may be time-consuming and disruptive to the business.
• The company's stock could be delisted from the Nasdaq Capital Market if it fails to regain compliance with the minimum bid price requirement.
• Potential changes in FDA regulations regarding laboratory developed tests (LDTs) could require premarket approval or clearance for the company's tests, increasing costs and delaying commercialization.
• The company is involved in securities class action and shareholder derivative lawsuits, the outcomes of which are uncertain.
• The company received notice from Kilroy Realty, L.P. of a potential event of default under that certain Office Lease for failure to pay Basic Rent and Additional Rent.

Future Outlook

The company expects losses to continue and is exploring strategic alternatives to address its financial challenges. Management expects that based on its currently planned business operations and the anticipated cost savings of the Restructuring Plans, currently available resources will not provide sufficient funds to meet its anticipated operating costs for at least the next 12 months from the Evaluation Period.

Management Comments

• We are currently prioritizing billable samples in geographies where we have payor coverage versus overall volume growth as one factor to potentially increase average selling price.
• We continuously take measures with the goal of improving that proportion by leveraging our Medicare coverage and the over 130 million total covered lives for our test, as well as increasing our appeals and administrative process with payors claim processing and medical affairs departments.

Industry Context

DermTech operates in the molecular diagnostics industry, specifically focusing on melanoma detection. The company's non-invasive approach using adhesive patches differentiates it from traditional biopsy methods. The market for skin cancer diagnostics is substantial, with millions of biopsies performed annually. DermTech's success depends on securing reimbursement coverage, expanding its market reach, and demonstrating the clinical and economic value of its tests.

Comparison to Industry Standards

• DermTech's revenue growth is modest compared to some other molecular diagnostic companies, but the company is in a turnaround situation.
• Exact Sciences, a competitor in cancer diagnostics, has achieved significant revenue growth with its Cologuard test, but it operates in a different market segment.
• The company's focus on non-invasive skin cancer detection aligns with the broader trend towards less invasive diagnostic procedures.
• The company's financial challenges are not uncommon for early-stage diagnostic companies, which often require significant capital investment and time to achieve profitability.

Legal Proceedings

• The company is involved in a securities class action lawsuit, In re Dermtech, Inc. Securities Litigation, Case No. 3:23-cv-1885-DMS-JLB (S.D. Cal.).
• The company is involved in a shareholder derivative lawsuit, Fleischman v. DermTech, Inc., et al., Case No. 23-cv-2289-AJB-BGS.

Stakeholder Impact

• Shareholders face the risk of stock dilution, delisting, and potential loss of investment value.
• Employees have been affected by workforce reductions and face uncertainty about the company's future.
• Customers may be concerned about the company's ability to continue providing its services.
• Suppliers may face extended payment terms or potential losses if the company is unable to meet its obligations.
• Creditors face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company is exploring strategic alternatives, including an acquisition, merger, or sale of assets.
• The company must regain compliance with Nasdaq's minimum bid price requirement by October 14, 2024.
• The company will continue to implement restructuring plans to reduce operating expenses.
• The company is evaluating the potential impact of the FDA's final rule on laboratory developed tests (LDTs).

Key Dates

Keywords

DermTech, financial results, Q1 2024, restructuring, going concern, revenue, net loss, strategic alternatives, DermTech Melanoma Test, biopsy, FDA, LDT, Nasdaq, delisting